Skip to main content
  • BIOFLOW-V: Orsiro’s TLF Rate Still Lower at 5 Years vs. Xience, but Difference No Longer Significant

    TV-MI, stent thrombosis rates were still significantly lower for Orsiro

    At 5 years, patients who underwent percutaneous coronary intervention (PCI) with the Orsiro stent showed numerically lower, but not statistically significantly different, rates of target lesion failure (TLF) compared to the Xience stent, according to new BIOFLOW-V trial results.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details